Dong-A ST concludes co-development agreement of immunotherapy with AstraZeneca

Published: 2018-01-15 13:05:41

Updated: 2018-01-15 13:05:41

Dong-A ST(CEO/Vice President Soo-Hyun Kang) announced on the 11^th that the company signed a co-development agreement of innovative immunotherapies with AstraZeneca, an English biotech company, at JP Morgan Healthcare Conference in San Francisco, USA, on the 10^th, 4pm.

With Dong-A ST Vice President Soo-Hyung Kang, Scientific Partnering and Alliance Head Kumar Srinivasan and persons concerned, t...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.